Timapiprant

Drug Profile

Timapiprant

Alternative Names: OC 459; OC-000459; ODC-9101

Latest Information Update: 30 Sep 2016

Price : $50

At a glance

  • Originator Oxagen
  • Developer Atopix Therapeutics; Oxagen
  • Class Antiallergics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Allergic rhinitis; Allergic rhinoconjunctivitis; Atopic dermatitis
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 28 Sep 2016 Phase-III clinical trials in Asthma in Russia (PO) before September 2016
  • 28 Sep 2016 Eleventa completes enrolment in its phase III trial for Asthma in Russia
  • 01 Oct 2015 Imperial College London initiates enrolment in the ORCA trial for Asthma (Treatment-experienced, rhinovirus challenge) in United Kingdom (NCT02660489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top